National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under ...
A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.
The 2026 GU ASCO annual meeting featured a urothelial carcinoma session and a discussant presentation by Dr. Tyler F. Stewart ...
A cohort analysis of patients treated with RC for MIBC across the United States was performed using the National Cancer Database. The primary outcome measure was overall survival (OS), defined as the ...
The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...
JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...
UroGen Pharma Ltd. (NASDAQ:URGN) on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto (mitomycin) for pyelocalyceal solution. The U.S. Food ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
Prediction of disease recurrence and progression for patients with non-muscle-invasive bladder cancer is a major clinical challenge. However, bladder cancer is progressively being regarded as a ...
HDAC 1–3 protein expression in bladder cancer tissue samples was investigated by immunohistochemical analysis of the TMA containing 174 specimens from patients with a primary urothelial carcinoma of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results